S1 File - Long-term mortality outcome of a primary care-based mobile health intervention for stroke management: Six-year follow-up of a cluster-randomized controlled trial

<b>Fig A.</b> Timeline for trial phase and post-trial follow-up phase in SINEMA. <b>Table A.</b> Full list of mortality outcomes with ICD-10 codes used in the present study. <b>Appendix A.</b> Definitions, measurement for intermediate outcomes in S1 File. <b>Appendix B.</b> Statistical analysis plan for intermediate outcomes in <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004564#pmed.1004564.s003" target="_blank">S1 File</a>. <b>Table B.</b> Baseline characteristics of participants who were followed and deceased at 70-month follow-up (<i>n</i> = 1,255). <b>Table C.</b> Baseline characteristics by status of follow-up among participants who survived at 70 months (<i>n</i> = 1,023). <b>Fig B.</b> Flow diagram for confirming mortality information from three sources. <b>Table D.</b> Baseline characteristics of participants of the SINEMA trial who died during 70-months follow-up post-baseline (<i>n</i> = 276). <b>Table E.</b> Baseline characteristics by intervention arms of participants who survived at 70-months post-baseline (<i>n</i> = 1,023). <b>Table F.</b> Baseline characteristics of participants in the SINEMA trial by vital status at 70-months post-baseline (<i>n</i> = 1,299). <b>Table G.</b> The adjusted hazard ratios (95% confidence intervals) of intervention on mortality in patients experiencing stroke at 70-month follow-up using sub-distribution model. <b>Fig C.</b> Long-term outcomes on cardiovascular cause-specific mortality in each pre-specified and post-hoc subgroup, minimally adjusted model. <b>Fig D.</b> Long-term outcomes on stroke cause-specific mortality in each pre-specified and post-hoc subgroup, minimally adjusted model. <b>Table H.</b> Effects (risk difference) of the SINEMA intervention on intermediate outcomes from baseline to 70 months among living patients (<i>n</i> = 979). <b>Table I.</b> Participants characteristics and intermediate outcomes at baseline and at the long-term follow-up (<i>n</i> = 979). (DOCX)